
Subdued growth headlines and a sustained focus on fiscal consolidation by the government give room for the RBI to cut…
Subdued growth headlines and a sustained focus on fiscal consolidation by the government give room for the RBI to cut…
Debt funds enjoyed a good run in FY13 as most categories gave over 9% returns in a benign interest rate…
Asset mobilisation by fixed maturity plans dipped to its second lowest in the last six financial years as interest rates…
Despite incentives to widen their geographical spread beyond the top 15 cities
Mutual fund houses saw an addition of nearly 34% to their debt asset base in FY13 as assets of income…
While mutual fund houses declined, in the same period when BSE Sensex gained more than 8%.
Despite a volatile financial year for the Indian equities, a majority of the mid- and small-cap funds managed to beat…
More than 44 lakh equity folios closed in 2012-13, reflecting the eagerness on the part of investors to exit equity…
RBI?s move to cut the repo rate by 25 bps was along expected lines, given the softening in non-food manufactured…
Direct plans, which became operational this year and allow investors to bypass distributors and save on commission, now contribute roughly…
The majority of the inflows into the six new fund offers of close-ended RGESS schemes seem to have come from…
It has been a tough fiscal for the mutual fund industry, particularly with respect to attracting investment into equity schemes.
Despite bouts of volatility, equities are likely to come back into reckoning this year, believes S Krishna Kumar, head, equity,…
Nearly a year after the country’s two premier bourses, BSE and NSE, started operations of their respective SME platform, the…
New schemes launched under the Rajiv Gandhi Equity Savings Scheme platform have got a dismal response as the delay in…
Sebi’s move to issue a framework on ?product labelling? is expected to help novice investors in assessing basic risks associated…
While the fund houses expressed confidence that they would be able to garner the minimum required limit of R10 crore…
AstraZeneca Pharma has decided instead to reduce its promoter shareholding to 75%.